Complement Ther Clin Pract 2011
83% of participants Achieved A1c less 7% Lost up to 11.3 kg (24.86lbs) Lower incidence of hypoglycemia (lower blood glucose) with tirzepatide Side effects: Mild to moderate gastrointestinal events
Vision loss associated with GLP-1 drugs is often permanent and has many people to file lawsuits against Eli Lilly over its tirzepatide weight-loss drug
Spiller H, Krenzelok E, Grande G, Safir E, Diamond J (1994)
Increasing healthcare awareness, growing disposable incomes, and expanding access to modern therapeutics are accelerating demand for advanced treatment options
Anatomical Target Sites: Inject subcutaneously (just under the shallow skin layer) into the abdomen, front thigh, or outer upper arm